Yoshida N, et al. – In this current study, using virtual histology intravascular ultrasound (VH–IVUS), researchers assessed the impact of CD14⁺⁺CD16⁺ monocytes on plaque vulnerability as well as relationship to fluctuating glucose levels in patients with asymptomatic coronary artery disease (CAD). Findings demonstrated an association of CD14⁺⁺CD16⁺ monocyte levels with coronary plaque vulnerability. In CAD patients on lipid–lowering therapy, CD16⁺ monocyte levels can be used as a biomarker for virtual histology thin-cap fibroatheroma (VH-TCFA). The balance of monocyte subsets might be altered by glucose fluctuations, in patients without diabetes mellitus (DM).